than $35 per month for a 30-day supply of, or a typical course of treatment with, such drug or product. (c) Identification of noncompliant drugs and products In the case that a direct-to-consumer advertisement described in subsection (a) does not include a written statement as required under such subsection and is not excepted with respect to such statement under subsection (b), the Secretary shall identify the prescription drug or biological product that is the subject of such advertisement as a drug or product advertised in violation of the requirement of subsection (a). The Secretary shall maintain a public list of all prescription drugs and biological products identified pursuant to the previous sentence. (d) Definitions In this section: (1) Current list price The term current list price , with respect to a prescription drug or biological product described in subsection (a) and a direct-to-consumer advertisement described in such subsection for such drug or product, means the wholesale acquisition cost (as defined in section 1847A(c)(6)) of such drug or product as of the first day of the quarter during which such advertisement is aired or otherwise broadcast. (2) Typical course of treatment The term typical course of treatment , with respect to a prescription drug or biological product described in subsection (a) and a direct-to-consumer advertisement described in such subsection for such drug or product, means the typical course of treatment associated with the primary indication addressed in such advertisement for which such drug or product is prescribed. .